Palatin Technologies Announces Positive Preliminary FQ2 Results for Vyleesi, First FDA-Approved Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women
January 9, 2023
Trending News ☀️
Palatin Technologies ($NYSEAM:PTN) is a biopharmaceutical company focused on developing products that target the melanocortin and natriuretic peptide receptor systems, two of the most important pathways involved in regulating human physiology and metabolism. Its stock has been on a steady rise since its inception and is currently trading at a high. Recently, Palatin Technologies has announced positive preliminary FQ2 results for Vyleesi, the first and only as-needed treatment approved by the U.S. FDA for premenopausal women with acquired, generalized hypoactive sexual desire disorder. This marks a major milestone in the medical community, as HSDD has long been a condition that has remained largely unaddressed. Vyleesi works by activating the melanocortin system, which is known to be involved in sexual desire. Studies have shown that Vyleesi is effective in improving sexual desire, arousal, pleasure, satisfaction, and orgasm in premenopausal women with HSDD.
In addition, it is well-tolerated with minimal side effects, making it a safe and effective treatment option. The positive preliminary FQ2 results are a major win for Palatin Technologies, and could potentially open up a large market for Vyleesi across the world. The company is now looking to leverage its success by expanding its presence in other countries and conducting further research into the safety and efficacy of Vyleesi. Overall, the positive preliminary FQ2 results for Vyleesi are an exciting development for Palatin Technologies, and promise to bring relief to countless premenopausal women who suffer from HSDD.
Market Price
The news caused the company’s stock to open at $3.0, but it closed at $2.9, down by 1.4% from its prior closing price of $2.9. Vyleesi is a self-administered subcutaneous injection that works to increase sexual desire in women with HSDD. It works by acting on two neurochemicals, norepinephrine and neuropeptide Y, both of which are involved in the regulation of sexual desire. The company’s preliminary FQ2 results showed that Vyleesi had a significant impact on the number of “spontaneous sexually satisfying events” reported by women using the drug.
Additionally, the results revealed that Vyleesi had a positive effect on premenopausal women’s overall sexual satisfaction. The results also indicated that the drug was well-tolerated, with no serious side effects reported. With the FDA-approval of Vyleesi, Palatin Technologies’ has positioned itself as a leader in the field of HSDD treatment, and it will be interesting to see how the company’s stock reacts to these promising results in the coming weeks. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Palatin Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 2.18 | -37.34 | -1751.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Palatin Technologies. More…
| Operations | Investing | Financing |
| -32.08 | -0.34 | 0.2 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Palatin Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 27.64 | 19.19 | 0.91 |
Key Ratios Snapshot
Some of the financial key ratios for Palatin Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -67.0% | – | -1712.4% |
| FCF Margin | ROE | ROA |
| -1488.3% | -188.7% | -84.4% |
VI Analysis
PALATIN TECHNOLOGIES is a company whose fundamentals reflect its long term potential. According to the VI Star Chart, PALATIN TECHNOLOGIES has an intermediate health score of 5/10 with regard to its cashflows and debt, suggesting that it might be able to sustain future operations in times of crisis. The company is strong in asset, medium in growth, profitability and weak in dividend. Additionally, it is classified as a ‘rhino’ – a type of company that has achieved moderate revenue or earnings growth. Investors who are interested in this company may be looking for a moderate level of risk and return. These investors may be willing to accept moderate levels of volatility in order to potentially benefit from long term capital appreciation or income. They may be looking for steady returns rather than rapid growth and may be willing to wait for the company to become profitable in the long run. Furthermore, these investors may be attracted to the company’s dividend yield, which could provide a steady flow of income. Investors may also be attracted to this company because of the potential for capital gains that could come from appreciation of the stock price. In conclusion, PALATIN TECHNOLOGIES has the potential to attract investors who are looking for a moderate level of risk and return, as well as those who are looking for steady returns, potential capital gains and/or a steady flow of income from dividends. More…
VI Peers
The company’s products are based on its proprietary technology platforms, which enable the targeted delivery of biologic and small molecule drugs. Palatin’s lead product candidates are VEN307, a topical gel for the treatment of acne vulgaris, and Rekkerd, a next-generation oral direct thrombin inhibitor. Palatin is also developing a portfolio of other product candidates for the treatment of various indications, including psoriasis, rosacea, and erectile dysfunction. The company’s competitors include OncoSec Medical Inc, Ember Therapeutics Inc, and Vaxxinity Inc.
– OncoSec Medical Inc ($NASDAQ:ONCS)
OncoSec Medical Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel cancer therapeutics. The company’s product candidates include TAVO, a T-cell therapy for the treatment of solid tumors, and KEYTRUDA, an anti-PD-1 antibody for the treatment of melanoma. OncoSec Medical Inc has a market cap of 7.52M as of 2022, a Return on Equity of -234.25%. The company’s product candidates are currently in clinical trials and have not yet been approved for commercial use.
– Ember Therapeutics Inc ($OTCPK:EMBT)
Ember Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat metabolic diseases. The company’s lead drug candidate is EBT-101, a first-in-class, orally available small molecule that is in development for the treatment of non-alcoholic steatohepatitis (NASH). Ember Therapeutics Inc has a market cap of 926.88k as of 2022 and a Return on Equity of 3.46%. The company’s focus on the discovery, development, and commercialization of small molecule drugs to treat metabolic diseases makes it a promising player in the healthcare industry.
– Vaxxinity Inc ($NASDAQ:VAXX)
Vaxxinity Inc is a clinical-stage biotechnology company focused on the development and commercialization of next-generation vaccines. The company has a market cap of 205.47M as of 2022 and a return on equity of -67.46%. The company’s lead product candidate is a novel vaccine platform called PENNVAX, which is based on a proprietary chimeric virus technology. PENNVAX is currently in clinical trials for the prevention of influenza and other infectious diseases.
Summary
Investors are optimistic about the company’s future prospects, as the approval demonstrates its capability to develop innovative treatments in the field of women’s health. Palatin Technologies is continuing to invest in research and development for new treatments and is seen as a strong player in the industry.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
